Ziv-aflibercept in metastatic colorectal cancer.

Biologics · 2014 · PMC3869833 · PMID 24368879

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

OS was significantly improved in the bevacizumab-naïve subset, but did not achieve significance in the prior-bevacizumab subset.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.